ChemoCentryx, Inc.
COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
Last updated:
Abstract:
The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
Status:
Application
Type:
Utility
Filling date:
19 Mar 2019
Issue date:
12 Sep 2019